Product Information
TRELEGY ELLIPTA 200-62.5-25 is a brand product labeled by GlaxoSmithKline LLC, priced at $11.2215 per EA under NDC 00173089314. Its NADAC has been published 280 times since Feb 17, 2021.
TRELEGY ELLIPTA 200-62.5-25
fluticasone furoate, umeclidinium bromide and vilanterol trifenatateStrength
200; 62.5; 25 ug/1; ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173089314
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Last Updated
6/17/2026
Active Ingredients
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA209482On Market Since
9/9/2020
Pharmacological Classes
Price Statistics
The NADAC for TRELEGY ELLIPTA 200-62.5-25 has been published 280 times since Feb 17, 2021, and over the history we have for it it has risen 16.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.2215 per EA |
|---|---|
| All-time high | $11.2215 (Jun 24, 2026) |
| All-time low | $9.5641 (Apr 21, 2021) |
| 52-week high | $11.2215 |
| 52-week low | $10.8535 |
| Median price | $10.1465 |
| Average price | $10.2872 |
| Largest weekly change | +3.0% (Jan 8, 2025) |
| Weeks tracked | 280 |
| Tracking since | Feb 17, 2021 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of TRELEGY ELLIPTA 200-62.5-25?
The current National Average Drug Acquisition Cost (NADAC) for TRELEGY ELLIPTA 200-62.5-25, manufactured by GlaxoSmithKline LLC, is $11.2215 per EA (NDC 00173089314), effective Jun 24, 2026.
How has the price of TRELEGY ELLIPTA 200-62.5-25 changed over time?
Over the history we have for it, the NADAC for TRELEGY ELLIPTA 200-62.5-25 has risen 16.6%. It has been tracked across 280 weekly CMS publications since Feb 17, 2021.
What are the highest and lowest recorded NADAC prices for TRELEGY ELLIPTA 200-62.5-25?
Since Feb 17, 2021, the NADAC for TRELEGY ELLIPTA 200-62.5-25 has ranged from a low of $9.5641 (Apr 21, 2021) to a high of $11.2215 (Jun 24, 2026), with a median of $10.1465 per EA.
Are there cheaper alternatives to TRELEGY ELLIPTA 200-62.5-25?
Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, TRELEGY ELLIPTA 200-62.5-25, is $11.1560 per EA — about 1% below TRELEGY ELLIPTA 200-62.5-25.
Who manufactures TRELEGY ELLIPTA 200-62.5-25?
TRELEGY ELLIPTA 200-62.5-25 (NDC 00173089314) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.
Related Drugs
Same classification